[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-transplant":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,49,85,110,138,158,192,217,247,278,301,324,348,377,408,429,451,471,496,518,540,560,586,611,645],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100565284","feasibility-and-plausible-effectiveness-of-a-lifestyle-intervention-in-kidney-transplant-recipients-heal-100565284",false,"NCT06640179","Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)","Prevention of Weight Gain and Impaired Glucose Metabolism Post Kidney Transplantation: A Pilot and Feasibility Study","HEAL","Inclusion Criteria:\n\n* Receiving a kidney transplant within the prior 3-5 months, with the transplant received from a deceased donor or living donor. NOTE: The patient will be eligible for randomization at 3 months following the kidney transplant, or at a subsequent time once clearance from the kidney transplant physician is given, provided that the time does not exceed 5 months following the kidney transplant.\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* \\>=18 years of age.\n* Body mass index (BMI) \\>22 kg\u002Fm2. There is no maximal BMI provided that the weight does not exceed the weight allowance of the dual-energy x-ray absorptiometer (DXA) that is used to assess body composition (maximal weight for the DXA is 350 pounds).\n* Ability to provide informed consent prior to participation in this study.\n* Ability to provide clearance from their kidney transplant physician to engage in the diet and physical activity components of the proposed intervention and to safely complete the proposed outcome measures.\n* Ability to walk for exercise.\n\nExclusion Criteria:\n\n* Females who are pregnant, breastfeeding, or reporting a planned pregnancy during the study period. Female participants of childbearing age who are not currently taking contraceptive medication, are not post-menopausal, or have not been surgically sterilized will need to agree to use a double barrier method of contraception.\n* History of bariatric surgery.\n* Currently prescribed an anti-obesity medication.\n* Report current medical condition or treatment for a medical condition that could affect body weight. These may include the following: diabetes mellitus; hyperthyroidism; inadequately controlled hypothyroidism; chronic liver disease; cancer; gastrointestinal disorders including ulcerative colitis, Crohn's disease, or malabsorption syndromes; etc.\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of \\>=160 mmHg or resting diastolic blood pressure of \\>=100 mmHg or not on a stable medical treatment to control hypertension (stable dose is defined as the same dose and type of medication for a period of at least 6 months).\n* Eating disorders that would contraindicate modifying eating or physical activity behaviors.\n* Alcohol or substance abuse.\n* Currently treated for psychological issues (i.e., depression, bipolar disorder, etc.) that is accompanied by the following: 1) not on a stable dose of medications for treatment within the previous 12 months, or 2) hospitalized for depression within the previous 5 years.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.","ALL","18 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether if it is feasible to implement a study of patients receiving kidney transplantation, to learn if these patients will complete selective outcomes measurements, and to examine if a lifestyle intervention may assist with preventing weight gain compared to standard medical care. The main questions it aims to answer are:\n\n* Is it feasible to recruit and retain patients who have undergone kidney transplantation into a study to compare standard medical care to standard medical care plus a lifestyle intervention focused on prevention of weight gain?\n* Will participants engage in the interventions and be compliant to the components of the interventions?\n* Will there be any difference between the interventions between the interventions for the occurrence of adverse events specific to kidney transplantation?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on preventing weight gain compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on body composition compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting glucose compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting insulin compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on insulin sensitivity compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical function compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on health-related quality of life compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on changes in dietary intake compared to standard medical care alone?\n* Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical activity and sedentary behavior compared to standard medical care alone?\n\nParticipants will:\n\n* Participants will continue with their standard medical care following kidney transplantation.\n* Participants only receiving standard medical care will also complete brief monitoring visits at week 6, 12, and 18.\n* Participants receiving the lifestyle intervention will attend weekly intervention sessions and will be recommended to modify their diet and physical activity behaviors in an effort to prevent weight gain.\n* Participants will complete outcome measurements as the start of the study and again after 6 months in the study.\n* After 6 months in the study, participants will also complete a brief intervention and answer other questions about their experience in the study.",[27,28,29],"Kidney Transplant","Overweight or Obese Adults","Glucose Control",[31,32,33,34,35],"kidney transplant","overweight","obesity","glucose control","weight control","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2024-12-17",{"date":44,"type":21},"2027-03-01",{"name":46,"class":47},"University of Kansas Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":48},"100645075","comparison-of-the-effects-of-general-anesthesia-and-combined-spinal-epidural-anesthesia-on-ferroptosis-humanin-and-mots-c-levels-in-renal-transplantation-100645075","NCT07678073","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION: A PROSPECTIVE CONTROLLED STUDY","Inclusion Criteria:\n\n* Patients aged 18-70 years with American Society of Anesthesiologists (ASA) physical status I-III.\n* Patients scheduled for elective living-donor allogeneic kidney transplantation.\n* Patients receiving sevoflurane-based general anesthesia as the anesthetic technique.\n* Patients receiving combined spinal-epidural anesthesia as the anesthetic technique.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 70 years.\n* Patients undergoing deceased-donor kidney transplantation.\n* Patients receiving total intravenous anesthesia (TIVA).\n* Patients who decline to participate in the study or are unable to provide informed consent.\n* Patients with American Society of Anesthesiologists (ASA) physical status IV or V.\n* Patients with a history of previous organ transplantation.\n* Patients with known or suspected mitochondrial disorders.\n* Patients with a history of chronic corticosteroid use.\n* Patients requiring red blood cell transfusion intraoperatively or within the first 24 postoperative hours.\n* Patients with a primary warm ischemia time \\>5 minutes, secondary warm ischemia time \\>30 minutes, or cold ischemia time \\>60 minutes.","70 Years",{"count":58,"type":21},68,[24],"Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated.\n\nThis prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis.\n\nThe primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.",[62,27,63,64,65],"Kidney Disease, End-Stage","Kidney","Kidney Disease","Renal Transplant",[67,68,69,70,71,72,73,74,75],"GENERAL ANESTHESIA","REGIONAL ANESTHESIA","KIDNEY TRANSPLANTATION","CELLULAR STRESS RESPONSE","CELLULAR STRESS","ANESTHESIA","HUMANIN","MOTS-c","FERROPTOSIS","2026-06-24",{"date":78,"type":40},"2026-07-01",{"date":80,"type":40},"2026-03-01",{"date":82,"type":21},"2026-10-15",{"name":84,"class":47},"University of Gaziantep",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":48},"100593807","alloreactive-memory-b-lymphocytes-and-anti-hla-sensitization-100593807","NCT07011238","Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization","Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization in Kidney Transplantation","ALLO-BMEM","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Rouen University Hospital patient monitored in the Nephrology and Kidney Transplantation Department, registered on the national kidney transplant waiting list\n* Carrier of HLA antibodies, including at least anti-HLA2, identified during the last screening\n* Notion of classic immune-promoting events including at least one previous transplant or pregnancy, or absence of a known immune-promoting event (naïve patient group)\n* Incompatible graft rate (IGR)\n\n  * IGR ≥ 85% (hyperimmunized patient group with anti-HLA polyreactivity) or\n  * IGR between 50% and 85% (immunized patient group with a more restricted repertoire of HLA reactivities) or\n  * IGR \\\u003C 50% (naïve patient group with no known history of immune-promoting events)\n* Person who has read and understood the information letter and does not object Not participating in the study\n* Affiliation to a social security scheme\n\nExclusion Criteria:\n\n* Patients who have received rituximab in the previous year (B-cell depleting therapy)\n* Patients undergoing an HLA desensitization protocol using plasmapheresis and\u002For rituximab\n* Patients with an active infection\n* Persons deprived of their liberty by an administrative or judicial decision or persons placed under judicial protection\u002Fguardianship or curatorship",{"count":94,"type":21},51,"1 Day","OBSERVATIONAL","In transplantation, B lymphocytes are major cellular players in the alloreactive humoral response through the production of antibodies targeting allogeneic HLA molecules expressed by the transplant. In subjects sensitized to HLA antigens, the contribution of pre-existing alloreactive memory B lymphocytes (Bmem) to allograft rejection phenomena after transplantation is now recognized. It has been proposed that the identification of these Bmem during the pre-transplant period could contribute to a better assessment of post-transplant immunological risk, allowing optimization of strategies to prevent humoral rejection. However, knowledge regarding the phenotypic and functional heterogeneity of Bmem as well as their clonal diversity is still extremely limited, not allowing discrimination between pathogenic and non-pathogenic alloreactive humoral responses. Such discrimination requires a better understanding of the modalities of differentiation of alloreactive B lymphocyte responses. To this end, this study aims to characterize the clonal, phenotypic and functional properties of alloreactive Bmem in subjects awaiting renal transplantation and sensitized to HLA antigens.",[27],[100],"B lymphocytes","2026-06-17",{"date":103,"type":40},"2026-06-22",{"date":105,"type":40},"2023-04-17",{"date":107,"type":21},"2028-06-17",{"name":109,"class":47},"University Hospital, Rouen",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":137},"100579938","phase-3-double-blind-randomized-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-ravulizumab-administered-intravenously-in-adult-participants-at-high-risk-of-delayed-graft-function-after-kidney-transplantation-100579938","NCT06830798","Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","AWAKE","Inclusion Criteria:\n\n* ≥ 18 years of age at the time of signing the informed consent\n* Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)\n* A candidate for kidney transplant from:\n\n  1. Donation after Circulatory Death (DCD) donor\n  2. High-risk Donation after Brain Death (DBD) donor\n\nExclusion Criteria:\n\n* Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification\n* Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.",{"count":119,"type":21},450,[121],"PHASE3","The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.",[124,125,27],"Delayed Graft Function","DGF",[124,125,27,127],"Ravulizumab",{"date":129,"type":40},"2026-06-18",{"date":131,"type":40},"2025-05-19",{"date":133,"type":21},"2028-08-30",{"name":135,"class":136},"Alexion Pharmaceuticals, Inc.","INDUSTRY",130,{"id":139,"slug":4,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":48},"100581857","NCT06855758","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with end-stage renal disease aged 18 years or above\n\nExclusion Criteria:\n\n* simultaneous multiple organ transplantation\n* known allergy to study medication\n* known pregnancy status\n* cancellation of surgery due to grafts or personal reasons\n* persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications\n* any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study",{"count":145,"type":21},150,[24],"Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.",[27,124,149],"Intraoperative Hypotension","2026-06-16",{"date":101,"type":40},{"date":153,"type":40},"2025-03-06",{"date":155,"type":21},"2027-06",{"name":157,"class":47},"Beijing Friendship Hospital",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":167,"conditions":168,"keywords":174,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":48},"100641683","impact-of-culture-of-perfusion-fluid-on-donor-derived-infection-management-and-outcome-in-liver-and-kidney-transplant-100641683","NCT07651137","Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant","PREVENT","Inclusion Criteria:\n\n* Adult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBO clinical center during the specified study periods\n* Availability of graft preservation fluid culture results\n* Signed informed consent\n\nExclusion Criteria:\n\n* None",{"count":166,"type":21},1400,"This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible donor-derived infections (infections transmitted from the donor organ).\n\nThe study will include all liver and kidney transplant recipients with available perfusion fluid culture results from 2021 until the start of the study (retrospective phase) and for two years after study initiation (prospective phase).\n\nThe study will assess how often high-risk microorganisms are identified in perfusion fluid, whether these findings are associated with complications or infections in recipients, and whether they affect patient outcomes, including mortality.",[169,170,171,27,172,173],"Liver Transplant Infection","Kidney Transplant Infection","Liver Transplant","Bacterial Infection","Donor-derived Infection",[175,176,177,178,179,180,181,31,182],"perfusion fluid","graft","transplantation","transplant recipients","infections","donor-derived infections","liver transplant","preservation fluid","NOT_YET_RECRUITING","2026-06-11",{"date":150,"type":40},{"date":187,"type":21},"2026-09-01",{"date":189,"type":21},"2029-08-31",{"name":191,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":48},"100643751","phase-4-phenotype-guided-vasoactive-medication-during-kidney-transplantation-100643751","NCT07633600","Phenotype Guided Vasoactive Medication During Kidney Transplantation","Intraoperative Circulation Phenotyping to Guide Vasoactive Medication in Kidney Transplant Recipients","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing kidney transplantation at Cedars-Sinai Medical Center\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent\n* Patients with contraindications to protocol vasoactive medications, as determined by the treating anesthesiologist\n* Patients in whom required intraoperative monitoring cannot be performed",{"count":200,"type":21},255,[202],"PHASE4","The goal of this clinical trial is to learn if vasopressin improves the body's response to intravenous fluids during kidney transplantation in patients who have relaxed blood vessels. Researchers will compare the results of vasopressin to those who received calcium chloride.",[27,205],"Fluid Management",[207,27],"Vasoactive Management","2026-06-04",{"date":210,"type":40},"2026-06-08",{"date":212,"type":21},"2026-06-01",{"date":214,"type":21},"2027-12-01",{"name":216,"class":47},"Jennifer Cutler",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":246},"100520364","phase-2-advancing-transplantation-outcomes-in-children-100520364","NCT06055608","Advancing Transplantation Outcomes in Children","Advancing Transplantation Outcomes in Children (CTOT-41)","ADVANTage","Inclusion Criteria:\n\n1. Participant and\u002For parent\u002Fguardian must be able to understand and provide informed consent\n2. Male or female, 13-20 years of age at time of enrollment\n3. Candidate for primary renal allograft from a living or deceased donor\n4. EBV IgG seropositive, defined as evidence of acquired immunity shown by the presence of IgG antibodies to viral capsid antigen (VCA) and EBV nuclear antigen (EBNA)\n5. EBV VCA IgM seronegative OR EBV VCA IgM seropositive on two occasions at least 3 months apart and an undetectable EBV PCR result within 1 month prior to enrollment\n6. If a female participant of childbearing potential, a negative pregnancy test prior to conducting any study procedures\n7. If participant has reproductive potential, agrees to use Food and Drug Administration (FDA) approved methods of birth control for the duration of the study\n8. Negative test result for latent tuberculosis infection by tuberculosis skin test (purified protein derivative \\[PPD\\]) or Tuberculosis (TB) blood test (interferon gamma release assay \\[IGRA\\] i.e., QuantiFERON, T- SPOT.TB) within 12 months\n9. In the absence of contraindication, vaccinations must be up to date per the Centers for Disease Control and Prevention (CDC) Guidelines and Division of Allergy, Immunology, and Transplantation (DAIT) Guidance for Patients in Transplant Trials\n\nEnrollment criteria for donor source and age will be expanded using a stepwise approach determined by safety monitoring. Expansion criteria will include recipients down to age 6 and living donors. Safety data from each step will be reviewed by the study team, DSMB and FDA. If no safety concerns are identified, inclusion criteria will be expanded.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to comply with study protocol\n2. Active infection requiring treatment, or viremia\n3. History of malignancy\n4. Receipt of any licensed or investigational live attenuated vaccine(s) within 4 weeks of enrollment\n5. Prior history of organ transplantation\n6. Listed for multi-organ transplant (e.g. heart- kidney, liver-kidney, multivisceral- kidney, lung- kidney)\n7. Active systemic autoimmune disease at time of enrollment\n8. Idiopathic Focal Segmental Glomerulosclerosis (FSGS), Membranoproliferative Glomerulonephritis (MPGN), C3 glomerulopathy, or atypical Hemolytic Uremic Syndrome (HUS) suspected at risk for recurrence\n9. Use of immunosuppressants, biologics (including IVIG), chronic corticosteroids or investigational drug(s) within 8 weeks of enrollment\n10. Known bleeding disorder\n11. Sustained platelet count \\\u003C 75,000 cells\u002Fmicroliters within 3 months of enrollment\n12. History of inherited hypercoagulability requiring therapy more than aspirin\n13. Panel Reactive Antibody (cPRA) greater than 80 percent\n14. Clinically significant unrepaired congenital heart disease causing hemodynamic compromise\n15. Uncontrolled diagnosed psychiatric disorder or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements\n16. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study\n\nRandomization Inclusion Criteria:\n\nIndividuals who meet all of the following criteria are eligible for randomization.\n\n1\\. If EBV serology to meet enrollment criteria was performed within 8 weeks of receiving IVIG, EBV VCA IgG and EBV EBNA IgG seropositivity, confirmed between enrollment and time of transplant\n\nRandomization Exclusion Criteria:\n\nIndividuals who meet any of these criteria are not eligible for randomization.\n\n1. Sustained WBC \\\u003C1500 or \\>20,000 per microliter within 3 months of randomization\n2. Sustained liver function tests (AST and\u002For ALT) \\> 2x normal within 3 months of randomization\n3. Active systemic autoimmune disease at time of transplant\n4. Known bleeding disorder\n5. Sustained platelet count \\\u003C 75,000 cells\u002Fmicroliters within 3 months of enrollment\n6. Current (within 45 days) or historical anti-HLA antibody to the donor prior to randomization\n7. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of randomization\n8. Panel Reactive Antibody (cPRA) greater than 80 percent at any point in time\n9. If a female participant of childbearing potential, a positive pregnancy test within 48 hours of randomization (all female participants of childbearing potential must complete a pregnancy test within 48 hours of randomization)\n10. Treatment with immunosuppressants within 8 weeks of randomization, except in the case of planned transplant standard of care\n11. Treatment with biologics (including IVIG) within 8 weeks of randomization","13 Years","20 Years",{"count":228,"type":21},200,[230],"PHASE2","This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.",[27],[31,234,235],"belatacept","sirolimus","2026-05-19",{"date":238,"type":40},"2026-05-20",{"date":240,"type":40},"2024-05-22",{"date":242,"type":21},"2028-06-30",{"name":244,"class":245},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",20,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},"100520402","phase-1-car-t-cell-therapy-for-desensitization-in-kidney-transplantation-100520402","NCT06056102","CAR-T Cell Therapy for Desensitization in Kidney Transplantation","Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation","Inclusion Criteria:\n\n1. Male or female patients aged 18-65 years with kidney failure requiring hemodialysis.\n2. Patients must meet one of the following two criteria:\n\n   1. All the following:\n\n      * Protocol-specific cPRA ≥99.5%\n      * No suitable living donor OR has been active in a kidney paired donation program but not received a match within 12 months\n      * Have blood group Type O or B, and predictive of a positive virtual crossmatch to an available deceased donor.\n      * United Network for Organ Sharing (UNOS) listed for kidney transplant for at least 1 year\n   2. Protocol-specific cPRA ≥99.9% Protocol-specific cPRA must be rounded from three significant figures measured ≤90 days from the time of enrollment (i.e., cPRA of 0.994500 or 0.998500 would be eligible) using the web-based OPTN cPRA calculator (https:\u002F\u002Foptn.transplant.hrsa.gov\u002Fresources\u002Fallocation-calculators\u002Fcpra-calculator\u002F); accounting for HLA-A, -B, -C, -DRB1, -DRB3\u002F4\u002F5, and -DQB1 Luminex Single Antigen Beads (SAB) with MFI ≥3000; 1 archived sample within 6 months of screening required.\n3. Based on center-specific listing policies, a cPRA in UNet Waitlist that is ≥99.5% (the candidate must be eligible for additional priority of kidneys equivalent to individuals with a 100% cPRA)\n4. Able to understand and give written informed consent to participate in all aspects of the study.\n5. Willing to stay within 2 hours of the home study site for at least 28 days after the last T cell infusion\n6. Subjects of reproductive potential must agree to use contraception for at least one year after CAR T Cell infusion\n7. In the absence of contraindication, vaccinations must be up to date per the DAIT Guidance for Patients in Transplant Trials and include TdAP\n8. Positive for EBV capsid IgG\n9. Negative testing for latent TB infection within 3 months prior to enrollment. Testing should be conducted using either a PPD or interferon-gamma release assay (i.e. QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection must complete appropriate therapy for Latent Tuberculosis Infection (LTBI). A subject is considered eligible only if they have a negative test for LTBI within 3 months prior to enrollment OR they have appropriately completed LTBI therapy prior to transplant. Latent TB infection treatment regimens should be among those endorsed by the CDC\n10. Hemoglobin ≥9g\u002FdL\n11. ANC ≥ 1,800\u002FμL, \\> 1,200\u002F μL for patients with Duffy-null associated neutrophil count (DANC)\n12. Absolute Lymphocyte Counts ≥500\u002FμL or CD3 T cell Count ≥150\u002FμL\n13. Platelet count ≥120,000\u002FμL\n\nExclusion Criteria:\n\n1. Subjects with indwelling catheters as primary access for hemodialysis\n2. Previous solid organ (except kidney) or bone marrow transplant\n3. BMI ≥35 kg\u002Fm\\^2\n4. Subjects who have preserved or oliguric urine output \\> 100 cc\u002Fday with history of recurrent UTI (2 in 6 months or 3 in 1 year, see study definitions)\n5. Subjects described in exclusion #4 with structural disease such as polycystic kidney disease, obstructive uropathy with nephrolithiasis or those otherwise at higher risk of urinary tract infections. Anuric subjects with structural kidney disease are not excluded\n6. Known active current or history of invasive fungal infection; any non-tuberculous mycobacterial infection that has been active or has required therapy within the last year. Any infection requiring hospitalization and IV antibiotics within 4 weeks of screening or PO antibiotics within 2 weeks\n7. History of HIV, chronic HBV, or chronic HCV, regardless of treatment\n8. Negative CMV serology\n9. Detectible viral load HBV, HCV, CMV, EBV, or BK by PCR\n10. Any B cell depleting or monoclonal antibody therapy within 6 months prior to enrollment\n11. Receiving ongoing immunosuppression including corticosteroids \\>5mg\u002Fday, intravenous immunoglobulin, cyclophosphamide, tacrolimus, mycophenolic acid, or azathioprine from 30 days prior to study entry\n12. Active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the investigator) autoimmune disease requiring prolonged immunosuppressive therapy, except Systemic Lupus Erythematosus that has been managed with a stable low dose of prednisone (5mg or less for at least 8 weeks) without other immunosuppressants or targeted biologics; or for renal-limited autoimmune conditions without risk for systemic manifestations (e.g. IgA nephropathy)\n13. Any chronic illness requiring uninterrupted anti-coagulation or anti-platelet therapy\n14. History of cirrhosis or severe liver disease, including abnormal liver profile (aspartate aminotransferase \\[AST\\], alanine aminotransferases \\[ALT\\] or total bilirubin \\> 3 times upper limit of normal at screening (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome)\n15. History of sickle cell disease, or systemic amyloidosis\n16. Cardiac clearance for transplant \\> 6 months old and\u002For any of the following: NYHA Class III or IV heart failure, unstable angina, left ventricular ejection fraction \\\u003C 40%, a history of recent (within 6 months) myocardial infarction or implantable cardioverter\u002F defibrillators and\u002For biventricular pacing.\n17. Moderate-severe pulmonary function abnormality, defined as resting oxygen saturation \\\u003C92% on room air or FEV1, TLC, or DLCO (after correction for hemoglobin) \\\u003C50% of predicted values\n18. Patients who have received any live vaccine within 30 days of planned leukapheresis\n19. Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening\n20. Pregnant, currently breastfeeding, or planning to become pregnant during the primary or post-transplant follow up of the study.\n21. Past or current social or medical problems; or findings from physical examination or laboratory testing that are not listed above, which in the opinion of investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study\n\nLymphodepleting Chemotherapy Eligibility:\n\nStudy entry eligibility must be re-assessed prior to starting lymphodepletion. In addition, subjects must undergo respiratory viral testing on nasal or nasopharyngeal swabs (per institutional practice) for SARS-CoV-2 and influenza within 7 days prior to the first planned lymphodepletion chemotherapy.\n\n1. If the subject is positive for influenza, Tamiflu® or equivalent should be administered per package insert. The subject must complete treatment and symptoms must be improving and either resolved or nearly resolved in the judgment of the treating investigator prior to receiving lymphodepleting chemotherapy and CAR T cells. Repeat influenza testing is not required prior to initiating lymphodepleting chemotherapy and CAR T cell infusion.\n2. If the subject tests positive for SARS-CoV-2, the subject will be managed per institutional practice. Subject will be eligible to initiate lymphodepleting chemotherapy and CAR T cell infusion once cleared from requirement for isolation according to institutional and\u002For CDC guidance.\n3. If testing is positive for another respiratory virus (e.g., as part of a multiplex respiratory pathogen panel in the course of testing for influenza or SARS-CoV-2), the lymphodepleting chemotherapy and CAR T cell infusion will be delayed for at least 7 days to be sure clinical symptoms of a viral infection do not develop. If clinical symptoms develop, the lymphodepleting chemotherapy and CAR T cell infusion will be delayed until resolution of these symptoms.\n\nCAR T Cell Infusion Eligibility:\n\nThe criteria below will be assessed by the investigator following lymphodepleting chemotherapy and before administration of CAR T cells. Subjects who do not satisfy these criteria may have CAR T cell infusion delayed until such time as criteria are satisfied. Subjects who receive lymphodepleting chemotherapy but in whom CAR T cell infusion is delayed \\>4 weeks after the first day of lymphodepleting chemotherapy will receive a second cycle of lymphodepleting chemotherapy prior to CAR T cell infusion. For subjects receiving fludarabine, a second cycle of cyclophosphamide can be administered, but fludarabine will not be repeated.\n\n1. Subjects must not have developed deterioration in performance status or overall clinical condition or new laboratory abnormalities that would, in the opinion of the treating investigator, render it unsafe to proceed with CAR T cell infusion. The following are specific conditions that warrant delaying CAR T cell infusion:\n\n   1. Requirement for supplemental oxygen to maintain peripheral oxygen saturation ≥95%.\n   2. Presence of clinically significant radiographic abnormalities on chest x-ray. Chest x-ray is not required to evaluate for radiographic abnormalities in the absence of suggestive symptoms or exam findings.\n   3. New cardiac arrhythmia not controlled with medical management. EKG is not required to evaluate for arrhythmia in the absence of suggestive symptoms or exam findings.\n   4. Hypotension requiring vasopressor support.\n   5. Active infection: Diagnostic test results indicating new bacterial, fungal, or viral infection within prior 48 hours.\n2. Subjects must have adhered to restrictions on pre-infusion therapy.","65 Years",{"count":246,"type":21},[257],"PHASE1","This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study will test whether new products called Chimeric Antigen Receptor T Cells (CAR T Cells), when given with chemotherapy, is safe and will reduce cPRA.\n\nThe main study will last up to 2 years: Participants will have up to 30 clinic or hospital visits over a one-year period. If a transplant takes place, there will be 9 more visits after transplant. Long term follow up is required by the Food and Drug Administration (FDA) for 15 years after receiving CAR T cell.\n\nThe primary objective is to evaluate the safety and feasibility of administering CART BCMA + huCART-19 following lymphodepletion, including determination of optimal tolerated regimen (OTR) and\u002For recommended phase 2 regimen, according to the incidence of dose limiting toxicity (DLT) in highly sensitized patients awaiting kidney transplant.",[27,260,261],"Kidney Failure","End Stage Renal Failure on Dialysis",[263,264,265,266,267,268,269],"Kidney transplant","CART-BCMA","huCART-19","Highly sensitized","cPRA","UNOS waiting list","End stage renal failure patients with cPRA >99.5%",{"date":271,"type":40},"2026-05-22",{"date":273,"type":40},"2024-05-09",{"date":275,"type":21},"2042-12-15",{"name":244,"class":245},3,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100638744","perceptions-of-kidney-transplant-recipients-regarding-the-role-of-artificial-intelligence-in-medicine-100638744","NCT07600541","Perceptions of Kidney Transplant Recipients Regarding the Role of Artificial Intelligence in Medicine","AITX","* Inclusion criteria\n\n  * Age ≥ 18 years\n  * Fluency in French or English\n  * Electronic consent given\n* Exclusion criteria\n\n  * Severe cognitive impairment preventing comprehension\n  * Technical inability to access the questionnaire",{"count":286,"type":21},1000,"The AITX study is an international, multicenter survey exploring how kidney transplant recipients perceive artificial intelligence (AI) in medicine and, specifically, a system that predicts graft loss risk. Through an open-ended online questionnaire distributed across transplant centers and patient associations in France and the United States, the study captures patients' expectations, concerns, and the perceived impact of AI-driven prediction on their daily lives. Responses are analyzed using large language models (LLMs) with systematic human verification. The study aims to ensure that the deployment of AI in transplantation is ethical, transparent, and patient-centered.",[27],[290,291],"artificial intelligence","survey","2026-05-13",{"date":238,"type":40},{"date":295,"type":40},"2026-04-15",{"date":297,"type":21},"2026-12-30",{"name":299,"class":47},"Paris Translational Research Center for Organ Transplantation",2,{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":48},"100638079","evaluation-of-an-instructional-video-about-medication-management-during-admission-and-medication-adherence-for-kidney-transplantation-and-in-the-outpatient-clinic-in-a-dutch-university-hospital-100638079","NCT07592624","Evaluation of an Instructional Video About Medication Management During Admission and Medication Adherence for Kidney Transplantation and in the Outpatient Clinic in a Dutch University Hospital.","MediT","Inclusion Criteria:\n\n* The patient is able to take the medication independently or with the help of someone else (professionals not included).\n* After admission, the patient is discharged to their own home or home of friend\u002Frelative.\n* The patient had a follow up at the outpatient clinic in the Erasmus Medical Center for at least one year after transplantation.\n* The patient is able to read the medication list or an illiteracy-friendly medication list.\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients who got discharged with a medication dispenser\n* Refusal to participate in the study.\n* Cognitive impairments that hinder participation.\n* Patients and\u002For family who can not understand (language barrier) the instructional video.",{"count":309,"type":21},308,[24],"The goal of this RCT is to evaluate the effect of the instructional video on improving patient compliance and reducing medication errors. The study will include adult kidney transplant recipients (18 years or older) at Erasmus MC who have undergone a kidney transplantation starting January 2026.\n\nThe main questions it aims to answer:\n\nThe primary aim of this study is to assess whether our developed video instruction, compared with the traditional verbal instruction, both of which are given shortly before training during admission, reduces the number of medication errors in kidney transplant patients.\n\nThe study will also examine the correlation between patient characteristics (such as age, comorbidities, and language proficiency) and medication errors. Additionally, patient-reported medication errors will be measured through a questionnaire completed during follow-up visits at the outpatient clinic, which is part of standard care.\n\nThe instructional video will be evaluated by a short questionnaire.",[27,313,314,315],"Adult","Medication Adherence","Instruction Videos","2026-05-11",{"date":318,"type":40},"2026-05-18",{"date":78,"type":21},{"date":321,"type":21},"2027-12-31",{"name":323,"class":47},"Erasmus Medical Center",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":48},"100340034","phase-1-study-of-combined-kidney-and-blood-stem-cell-transplant-from-a-brother-or-sister-donor-100340034","NCT03707262","Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor","Donor Chimerism and Graft Survival Following Combined HLA-Identical Sibling Living Donor Kidney and Hematopoietic Stem Cell Transplantation Utilizing a Conditioning Regimen of Total Lymphoid Irradiation and Rabbit Anti-Thymocyte Globulin","Recipient Inclusion Criteria:\n\n1. Males and females ages 18 years and older receiving living donor kidney transplant from an HLA-identical sibling at UCLA Medical Center.\n2. Agrees to participate in the study and is able to give informed consent.\n3. Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three to six months of the trial at the physician's discretion.\n4. Meets institutional criteria for kidney and HSPC transplant.\n5. No known contraindication to administration of rATG or radiation.\n6. If patient is a female of reproductive potential (i.e., no documented absence of ovaries or uterus, history of tubal ligation, or post-menopausal status) patient must be confirmed not pregnant by a serum or urine pregnancy test) and must agree to practice a reliable form of contraception including hormonal treatments, barrier methods or intrauterine device for at least 12 months post-transplant. Karnofsky Performance Score ≥ 70.\n7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 40% by MUGA (Multi Gated Acquisition) scan or echocardiogram.\n8. Adequate pulmonary function defined as FVC and DLCO of greater than or equal to 50% of predicted.\n9. Adequate liver function defined as total bilirubin ≤ 1.5 times the upper limit of normal and AST\u002FALT ≤ 2.0 times the upper limit of normal.\n10. Adequate social support based on evaluation by the UCLA renal transplant team licensed clinical social worker.\n\nRecipient Exclusion Criteria:\n\n1. Donor is identical twin.\n2. ABO incompatibility with donor.\n3. Previous solid organ transplant\n4. Multi-organ transplantation\n5. Previous treatment with rATG or a known allergy to rabbit proteins\n6. History of active malignancy within the past 5 years with the exception of non-melanomatous skin cancer.\n\n   a. History of another primary malignancy except for: i. Malignancy treated with curative intent and with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence ii. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease iii. Very low risk and low risk cancer adequately treated or on active surveillance b. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, and DCIS)\n7. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n8. Leukopenia (with a white blood cell count \\\u003C 3,000\u002F µL) or thrombocytopenia (with a platelet count \\\u003C 100,000\u002F µL).\n9. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C).\n10. Positive HLA DSA\n11. Seropositivity for HIV 1, HIV 2, HTLVI, HTLV II\n12. Active West Nile Virus infection\n13. Renal disease with high risk of recurrence (i.e., focal segmental glomerulosclerosis).\n14. Advanced hepatic fibrosis or cirrhosis secondary to hepatitis B and\u002For C diagnosis.\n15. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; active extra-renal autoimmune disease requiring immunosuppression.\n16. Active extra-renal autoimmune disease requiring immunosuppression.\n17. Neuropsychiatric illness that precludes the ability to give informed consent and\u002For places the patient as high risk for non-compliance with the safety monitoring requirements of the study.\n18. May not have received other immunosuppressive medications, including but not limited to alemtuzumab, belatacept, sirlolimus, everolimus, azathioprine, basiliximab, and eculizumab within six months of the study treatment. Use of corticosteroids prescribed for a time-limited indication (\\\u003C\u002F= 4 weeks) and stopped at least 4 weeks before the kidney transplant is acceptable.\n19. May not have received immunotherapy drugs such as immune checkpoint inhibitors (e.g. pembrolizumab, nivolumab, and ipilimumab), tumor necrosis factor inhibitors, rituximab, and interleukin-2 within six months of the study treatment.\n20. Current or active abuse of alcohol and\u002For drugs within last 6 months.\n21. BMI 40 or greater.\n\nDonor Inclusion Criteria:\n\n1. HLA-identical sibling on high-resolution HLA typing who is ≥18 years of age.\n2. Meets institutional criteria for living kidney and allogeneic HSPC transplant donation.\n3. Medically fit to tolerate peripheral blood apheresis, including weighing ≥110 pounds, hemoglobin ≥ 11 g\u002FdL, white blood cell count ≥ 3,000\u002FµL, and platelets ≥120,000\u002FµL.\n4. Normal serum chemistry and coagulation studies; or, if abnormal, the differences are not considered clinically significant.\n\nDonor Exclusion Criteria:\n\n1. Recipient is identical twin.\n2. ABO incompatibility with recipient.\n3. Medically unfit to tolerate peripheral blood apheresis (small body size, poor vascular access, not a suitable candidate for placement of a central catheter, etc.).\n4. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n5. Seropositivity for HIV 1, HIV 2, HTLV I, HTLV II\n6. Active West Nile Virus infection\n7. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C)\n8. Psychiatric, addictive, neurological, or other disorder that compromises ability to give true informed consent for participation in this study\n\n   1. History of active malignancy within the past 5 years with the exception:Adequately managed malignancy within the past two years with low risk of recurrence may be acceptable as per clinician discretion\n   2. Adequately managed non-melanoma skin cancer\n   3. Adequately managed carcinoma in situ e.g., cervical cancer in situ, and DCIS\n9. No current or recent use of oral anti-coagulants. (For the purpose of this study, recent is defined as less than 60 days prior to apheresis.). Note: Use of aspirin and non-steroidal anti-inflammatory drugs, for pain and inflammation management purposes, are permitted to enroll in the study, but these drugs must be stopped 14 days prior to apheresis, however subjects who are taking aspirin for its anti-platelet\u002Fanti-thrombotic effect, are excluded.",{"count":332,"type":21},15,[257,230],"The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor.\n\nThe investigational treatment is started after kidney transplant. It begins with a regimen of a drug called rabbit anti-thymocyte globulin (rATG) combined with radiation therapy (known as total lymphoid irradiation, or TLI) to the lymph nodes and spleen. This is followed by an infusion of blood stem cells, which will be donated by the same sibling who donated their kidney. Researchers think that this treatment allows immune cells from the donor and recipient to live side by side, a condition referred to as \"mixed chimerism.\" Mixed chimerism may help create a state of \"tolerance\" in kidney transplant recipients in which all immunosuppressive medications can be stopped without rejection of the transplanted kidney.\n\nThis study will test whether (1) the investigational treatment will allow patients to stop immunosuppressive medications after their kidney transplant and (2) if the treatment impacts the rate of kidney rejection and the side effects of immunosuppressive medications.",[336,337,27],"Renal Transplant Rejection","Tolerance",[337,27],"2026-05-06",{"date":341,"type":40},"2026-05-08",{"date":343,"type":40},"2019-11-06",{"date":345,"type":21},"2027-05",{"name":347,"class":47},"Jeffrey Veale, MD",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":356,"targetDuration":358,"studyType":96,"phases":4,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100635349","graftassure-lowering-allograft-rejection-by-combination--galactic-trial-100635349","NCT07551531","GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial","GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial: A Multi-Center Registry Study Assessing Transplanted Kidney Status","GALACTIC","Inclusion Criteria: Prospective Participant\n\n1. 18 years of age or older.\n2. ≥ 2 weeks post-kidney transplant at the time of first sample collection.\n3. Provides legally effective informed consent.\n4. Agrees to comply with all study procedures.\n\nInclusion Criteria: Historical Control Participant\n\n1. 18 years of age or older\n2. Has a minimum of three clinical evaluations per year post-transplant.\n\nExclusion Criteria: Prospective Participant\n\n1. Has received transplanted kidney from their identical twin.\n2. Has a history of another previously transplanted organ in situ, other than a prior kidney transplant.\n3. Has received an allogenic bone marrow graft or hematopoietic stem cell transplantation (HSCT).\n4. Self-reports as pregnant.\n5. Has a current malignancy, other than low-grade malignancy.\n6. Actively enrolled in another cfDNA assay-based trial.\n7. In the opinion of the investigator, participation in this study would pose a risk to data integrity or to the participant's safety and welfare.\n\nExclusion Criteria: Historical Control Participant\n\n1. Has received a kidney transplant from their identical twin.\n2. Has a history of another previously transplanted organ in situ, excluding previous kidney transplant.\n3. Has a current malignancy, other than low-grade malignancy.\n4. Self-reported pregnancy during the historical data time period.",{"count":357,"type":21},5000,"3 Years","The GALACTIC Registry study purpose is to validate the Combination Model-score (CM-score) for increased accuracy in the percentage of the positive predictive value (PPV) of allograft rejection results for the GraftAssure (GraftAssureCore and GraftAssureDx) assay. This will also be correlated with the biopsy yield and treatment decisions. The GraftAssure assay is a diagnostic test intended for the quantitative measurement of dd-cfDNA in plasma from kidney transplant recipients. The test is minimally invasive, and is intended to be used in conjunction with standard clinical assessment and other laboratory findings as an aid in the detection of allograft rejection.",[27],[31,362,363,364,365,366,367],"dd-cfDNA","cell-free DNA","allograft rejection","donor derived cell-free DNA","kidney rejection","rejection","2026-04-27",{"date":370,"type":40},"2026-05-01",{"date":372,"type":21},"2026-06",{"date":374,"type":21},"2033-06",{"name":376,"class":136},"Insight Molecular Diagnostics",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":385,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":407},"100517155","phase-4-empagliflozin-treatment-in-kidney-transplant-recipients-100517155","NCT06013865","Empagliflozin Treatment in Kidney Transplant Recipients","An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)","SEKTR","Inclusion Criteria:\n\n1. Adult (\\>18 years of age) male and female recipients (all races and ethnicities)\n2. Subject must be able to understand and provide consent\n3. Recipient of a primary or secondary kidney transplant at least 3 months or longer since transplant\n4. For subjects with T2DM or post-transplant diabetes (PTDM), measured kidney function by CKD epi eGFR must be 30mL\u002Fmin\u002F1.73m2 to 59 mL\u002Fmin\u002F1.73m2 or CKD epi eGFR 60 mL\u002Fmin\u002F1.73m2 with urinary albumin:creatinine ratio 30 mg\u002Fg (or protein:creatinine 100 mg\u002Fg).\n5. For subjects without T2DM or PTDM: measured kidney function by CKD epi eGFR must be 20mL\u002Fmin\u002F1.73m2 to 59mL\u002Fmin\u002F1.73m2 or CKD epi eGFR 60 mL\u002Fmin\u002F1.73m2 with urinary albumin:creatinine ratio 30 mg\u002Fg (or protein:creatinine 100 mg\u002Fg).\n\nExclusion Criteria:\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n2. History of prior pancreas transplant\n3. CKD epi eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2 for those with T2DM or \\\u003C 20 mL\u002Fmin\u002F1.73m2 for those without T2DM or anyone with 5mL\u002Fmin\u002F1.73m2 fall in eGFR per year\n4. Uncontrolled type 2 diabetes mellitus with most recent A1C\\>12%\n5. History of \\>2 urinary tract infections per year or UTIs requiring admission in the last year, or urosepsis in the last year.\n6. Use of SGLT2i within 90 days\n7. Documented allergy to SGLT2i\n8. History of Type I diabetes mellitus\n9. History of diabetic ketoacidosis\n10. Indwelling foley catheter or urinary diversion\n11. Acute rejection in the prior 3 months\n12. Acute MACE event within 3 months of the study\n13. Severe congestive heart failure (NYHA functional class III or higher)\n14. Active mucocutaneous mycotic infection of the groin or external genitalia.\n15. History of amputation due to peripheral vascular disease and\u002For diabetic foot ulcers within prior year\n16. History of malignancy except non-melanoma skin cancer within 2 years of screening\n17. Known of active current viral, fungal, mycobacterial, or other infections (including, but not limited to tuberculosis and atypical mycobacterial disease)\n18. HIV infected subjects, including those who are well controlled on anti-retrovirals\n19. Recent (within 6 months) Positive Hep B PCR or active disease\n20. Hepatitis C virus antibody positive (HCVAb+) subjects who have failed to demonstrate sustained viral remission for more than 12 weeks (after anti-viral treatment)\n21. Active pregnancy in a female transplant recipient\n22. A condition, in the eyes of the investigator, that precludes inclusion into the study.","19 Years",{"count":387,"type":21},264,[202],"Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.",[27,391],"Chronic Kidney Disease",[393,394,260,395,396],"Transplant","Diabetes","Rejection","Proteinuria","2026-04-16",{"date":399,"type":40},"2026-04-21",{"date":401,"type":40},"2024-04-05",{"date":403,"type":21},"2030-03-31",{"name":405,"class":406},"VA Office of Research and Development","FED",5,{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":415,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":428,"locationsCount":48},"100633876","personalized-stories-for-pediatric-kidney-recipients-100633876","NCT07532382","Personalized Stories for Pediatric Kidney Recipients","Generating Personalized Stories With Artificial Intelligence for Pediatric Kidney Recipients","Inclusion Criteria:\n\n* Age 5-12 years inclusive at enrolment.\n* Recipient of a kidney transplant.\n* Clinically stable at enrolment (no active rejection, acute infection, or current hospitalization for a graft-related complication).\n* Fluency in French or English.\n* Written informed consent from parent(s)\u002Flegal guardian(s); child assent when age-appropriate.\n\nExclusion Criteria:\n\n* Severe cognitive impairment precluding engagement with narrative content.\n* Mental state not allowing participation.\n* Family unwilling or unable to commit to the study timeline and interview requirements.","5 Years","12 Years",{"count":418,"type":21},100,"Pediatric kidney transplant recipients often face major psychosocial challenges that are difficult to address with existing tools. This study evaluates whether clinically supervised AI can generate personalized, age-adapted therapeutic stories for these children and their families.",[27],[422],"Artificial intelligence","2026-04-08",{"date":295,"type":40},{"date":80,"type":40},{"date":427,"type":21},"2026-12-01",{"name":299,"class":47},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":48},"100538232","evaluation-of-thiosulfate-enhanced-organ-preservation-solution-in-kidney-transplantation-100538232","NCT06288152","Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation","Inclusion Criteria:\n\n* 18 years of age and over\n* End-Stage Renal Disease\n* Receiving a kidney transplant from a deceased donor (NDD or DCD)\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Inability to provide informed consent\n* Living donor kidney recipients\n* Pregnant individuals\n* Known allergy to study medication or its components (non-medicinal ingredients)\n* Multiorgan transplant patients such as simultaneous kidney pancreas or liver kidney transplants\n* Currently enrolled in another interventional transplant clinical trial, or another clinical trial that in the opinion of the QI and PI would greatly impact the results of this study.",{"count":436,"type":21},120,[24],"End-stage renal disease (ESRD) is a significant clinical problem for which dialysis or transplantation is required. The current need for kidneys for transplantation vastly exceeds the supply available from live donors, necessitating the use of kidneys from deceased donors. However, kidneys from deceased donors are associated with reduced viability, as lack of blood supply upon cardiac death increases tissue damage. In addition, the standard protocol for cold preservation of donor kidneys between procurement and transplantation increases the risk of delayed donor kidney function by 23% for every 6-hours of storage. Moreover, compared to other organs, the kidney is particularly prone to transplantation-induced injury due to its high metabolic activities and oxygen consumption. Hence, any minor disturbances in blood supply can easily lead to kidney injury. Therefore, it is not surprising that deceased donor kidneys have a low tolerance for damage associated with lack of blood supply. The focus of the investigators research has been to pioneer the development and supplementation of existing kidney preservation solutions with novel hydrogen sulfide (H2S) donor molecules to improve kidney viability for clinical transplantation. Specifically, the investigators demonstrated that supplementation of standard kidney preservation solutions with non-clinically viable H2S donor molecules significantly increased donor kidney protection and prolonged transplant recipient survival in murine and porcine models of kidney transplantation. Having shown the same salutary effect using sodium thiosulfate (STS; a clinically viable H2S donor drug) in rat kidney transplantation, the investigators aim to repeat this work using STS in porcine and clinical kidney transplantation.\n\nThis single-blind study will enroll participants receiving a kidney transplant. Through randomization, half of the participants will receive STS through administration into the pump the kidney is placed on after procurement from the donor and before transplant to the recipient. Participants will be followed for 1-year post transplant where blood and urine will be collected to determine graft function.",[65,27],[441,393,442,63],"Thiosulfate","Renal","2026-04-07",{"date":445,"type":40},"2026-04-13",{"date":447,"type":40},"2025-05-03",{"date":44,"type":21},{"name":450,"class":47},"Alp Sener",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100580143","tacrolimus-and-risk-factors-for-glucose-metabolism-disorders-in-kidney-transplant-patients-100580143","NCT06833463","Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients","TARGET","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Recipients of a kidney transplant from a living or deceased donor\n* Standard immunosuppressive regimen post-kidney transplantation (KTx) including Envarsus®\n* LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice\n* Informed patient consent to participate in the study\n\nExclusion Criteria:\n\n* Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs\n* Random glycemia\u002FHbA1c levels justifying a diagnosis of diabetes at the time of study enrollment\n* Kidney retransplantation\n* Recipients of a multi-organ transplant\n* Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss\n* Use of flozins for renal or cardiac indications\n* Chronic use of drugs affecting carbohydrate metabolism, such as glucocorticosteroids",{"count":436,"type":21},"Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and infections.\n\nOne of the main medications used after a kidney transplant, called tacrolimus, can contribute to these sugar problems. Tacrolimus helps protect the new kidney, but it can also harm the cells in the pancreas that produce insulin, a hormone that controls blood sugar. Other factors, such as stress on the body and insulin resistance, can make things worse.\n\nThe effect of tacrolimus on blood sugar may depend on how the body processes the drug. Some people break down tacrolimus quickly (fast metabolizers), so they need higher doses to reach the right level in their blood. Others break it down more slowly (slow metabolizers) and require lower doses. Doctors can measure how fast someone metabolizes tacrolimus using aparameter called the concentration-to-dose (C\u002FD) ratio.\n\nThis study aims to find out what increases the risk of developing blood sugar problems after a kidney transplant. It will focus on how quickly patients process tacrolimus and whether this affects their risk of developing diabetes. The study will also look at how common these issues are in kidney transplant patients in Poland.",[27],"2026-04-01",{"date":463,"type":40},"2026-04-02",{"date":465,"type":40},"2025-05-29",{"date":467,"type":21},"2028-01-30",{"name":469,"class":136},"Chiesi Poland Sp. z o.o.",6,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":48},"100619733","kidney-protective-jacket-100619733","NCT07348458","Kidney Protective Jacket","The Effect of Intraoperative Thermal Kidney Insulation on Current Kidney Transplantation Surgical Practices","KPJ","Inclusion Criteria:\n\n* All deceased and living donor kidneys that are deemed suitable for transplantation\n* All suitable recipients who are 18 years or greater, and undergoing their first or second kidney transplant\n* All recipients must be able to provide full informed consent\n\nExclusion Criteria:\n\n* Paediatric donor kidneys (kidneys from donors \\\u003C 16 years in age)\n* Patients with a known allergy or hypersensitivity to silicone",{"count":246,"type":21},[24],"This is a safety study designed to investigate the safety of utilizing the Kidney Protective Jacket (KPJ)™ during kidney transplantation. In general, we aim to use the device in all possible recipients, aiming to demonstrate its safety in the variable circumstances that may arise during kidney transplantation, e.g. single or multiple renal vessels, different-sized kidneys, and variable recipient size and weight.",[27],[263,484,485,486,475,487],"Renal transplant","Second warm ischaemic time","Ischaemia-reperfusion injury","Graft cooling","2026-03-23",{"date":490,"type":40},"2026-03-25",{"date":80,"type":40},{"date":493,"type":21},"2026-12-31",{"name":495,"class":136},"iiShield",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":56,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":332},"100509752","phase-2-assessment-of-biomarker-guided-cni-substitution-in-kidney-transplantation-100509752","NCT05917522","Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","Assessment of Biomarker-Guided Calcineurin Inhibitor (CNI) Substitution In Kidney Transplantation (RTB-015)","Inclusion Criteria:\n\nObservational Study:\n\n1. Subject must be able to understand and provide informed consent\n2. Received (within 14 days) or candidate for an ABO-compatible kidney transplant, including A2 to B\n3. Panel Reactive Antibody \\\u003C=60% as determined by local site\n4. Virtual cross-match negative as determined by local site or Donor Specific Antibody (DSA) negative by central lab within 14 days post-transplant\n5. Female subjects of childbearing potential must have a negative pregnancy test upon study entry\n6. All subjects with reproductive potential must agree to use highly effective contraception for the duration of the study (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol)\n7. Hepatitis C Virus Ab positive subjects with negative Hepatitis C Virus polymerase chain reaction (HCV PCR) are eligible if they have spontaneously cleared infection or are in sustained virologic remission\n8. Vaccines up to date as per Division of Allergy, Immunology, and Transplantation (DAIT) guidance for patients in transplant trials (Refer to Manual of Procedures).\n9. Triple Immunosuppression - Calcineurin Inhibitor\u002FMycophenolic Acid\u002FSteroid (CNI\u002FMPA\u002Fsteroid)\n\n   1. CNI (Tacrolimus (TAC), target trough \\[C0\\] level: 0-3 mo, 8-12 ng\u002FmL; 4-6 mo, 6-10 ng\u002FmL; \\>6 mo, 5-8 ng\u002FmL\\])\n   2. MPA \\[target dose: mycophenolate mofetil \\>=500 mg bid or mycophenolate sodium \\>=360 mg bid\\]); and\n   3. Glucocorticoid, with a minimum dose equivalent to 5mg of prednisone per day\n\nNested Randomized Control Trial (RCT):\n\n1. Subject must be able to understand and provide informed consent\n2. A 6-month protocol biopsy free of Biopsy Proven Acute Rejection (BPAR)(by Central Pathology Core)\n3. Negative 6-month serum test for DSA (by Central HLA Core)\n4. eGFRCKD-EPI 30-90 ml\u002Fmin\u002F1.73m\\^2 at 6 months\n5. Has a verified negative purified protein derivative (PPD) or negative testing for tuberculosis using an approved IGRA blood test, such as QuantiFERON Gold TB or T-SPOT-TB assay OR has completed treatment for latent tuberculosis and has a negative chest x-ray. PPD or IGRA testing must occur within 52 weeks prior to randomization. These requirements apply as well to prior recipients of Bacille Calmette-Gurin (BCG) vaccination\n6. Minimum Mycophenolate mofetil (MPA) dose (MPA 500 mg po bid, or Mycophenolate sodium 360 mg po bid)\n7. Minimum Prednisone dose of 5mg per day\n8. Hepatitis C Virus Ab positive subjects with negative HCV PCR are eligible if they have spontaneously cleared infection or are in sustained virologic remission\n9. Hepatitis C Virus negative recipients of a Hepatitis C Virus positive organ are eligible if they have undergone treatment and are in sustained virologic remission\n10. Female subjects of childbearing potential must have a negative pregnancy test upon study entry\n11. All subjects with reproductive potential, must agree to use highly effective contraception the duration of the study-specific methods may be listed, if applicable\n\nExclusion Criteria:\n\nObservational Study:\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol including a mandated 6-mo kidney transplant biopsy\n2. Non-Kidney Transplant (KTx) (pre-existing or concurrent)\n3. Current use of immunomodulatory agents (including but not limited to: Rituximab, anti-Tumor necrosis factor(TNF) Monoclonal antibodies (mAb), or Belatacept, abatacept, Janus kinase inhibitors)\n4. Transplant in which the kidney donor is the recipient's Identical twin\n5. Epstein-Barr virus (EBV) sero-negative KTx recipient\n6. Chronic obstructive pulmonary disease (COPD)\n7. Untreated Latent Tuberculosis (TB)\n8. Human immunodeficiency virus (HIV) infection\n9. Active Hepatitis B infection (HBsAg+ or anti-HBcore +)\n10. Enrollment in another investigational trial\n11. Current, diagnosed, mental illness or current, diagnosed or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements\n12. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of enrollment\n13. Use of investigational drugs within 8 weeks of participation\n14. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study\n15. Use of Campath(R)\n\nNested Randomized Control Trial (RCT):\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n2. Biopsy Proven Acute Rejection (BPAR) or treated clinically-diagnosed rejection in the 6 months following enrollment in the Observational Study\n3. Positive for a Donor Specific Antibody (DSA) 0-6 months post-kidney transplant\n4. Acute Banff interstitial (i) score \\>0 on a 6-month protocol biopsy as determined by core pathology read\n5. Presence of recurrent on de novo glomerulonephropathy 0-6 months post-kidney transplant\n6. Presence of active infection including BK virus (BKV), Cytomegalovirus (CMV) or EBV viremia by Polymerase chain reaction (PCR) analysis\n7. Unable or unwilling to undergo protocol biopsies\n8. Not on Tacrolimus\u002FMycophenolic Acid (MPA)\u002FPred\n9. Unable to administer therapy s.c.\n10. Thrombocytopenia (\\\u003C50,000\u002Fmm\\^3)\n11. Pregnant, or unwilling to practice highly effective birth control\n12. Use of immunomodulatory agents (including but not limited to Rituximab, anti-TNF mAb, or Belatacept, abatacept, Janus kinase inhibitors) \\* since enrollment, other than cytolytic agents (i.e., Thymoglobulin(R)or Campath(R) or Basiliximab(R) used for induction therapy at the time of transplant\n13. Use of investigational drugs since transplant\n14. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study",{"count":504,"type":21},800,[230],"800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR\u002FDQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18 months monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM).\n\nThe primary objective of the Observational Study is to test the validity of the HLA-DR\u002FDQ mMM score as a prognostic biomarker for stratification of post-transplant alloimmune risk. Whereas the objective of the Nested RCT is to test whether a superior outcome in kidney function (primary endpoint), as well as secondary endpoints (neurocognitive function, and life participation PROM), will be achieved in patients who are transitioned from Tacrolimus (TAC) to abatacept, while maintaining efficacy (freedom from biopsy proven acute rejection).",[27],[27,509,510],"Abatacept","HLA-DR\u002FDQ mMM","2026-03-19",{"date":488,"type":40},{"date":514,"type":40},"2023-12-07",{"date":516,"type":21},"2029-07",{"name":244,"class":245},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":254,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":539},"100580062","phase-3-an-efficacy-safety-and-tolerability-study-of-vx-880-in-participants-with-type-1-diabetes-with-a-kidney-transplant-100580062","NCT06832410","An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant","Key Inclusion Criteria:\n\n* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence\n* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks\n* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study\n\nKey Exclusion Criteria:\n\n* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks\n* Participants had \\>1 kidney transplant procedure\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":526,"type":21},10,[121],"This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.",[530,27],"Type 1 Diabetes","2026-03-18",{"date":488,"type":40},{"date":534,"type":40},"2025-03-31",{"date":536,"type":21},"2027-09-17",{"name":538,"class":136},"Vertex Pharmaceuticals Incorporated",7,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":48},"100552427","non-invasive-evaluation-of-graft-condition-in-adult-patients-with-kidney-transplant-using-ultrasound-localization-microscopy-and-multispectral-optoacoustic-tomography-100552427","NCT06472947","Non-invasive Evaluation of Graft Condition in Adult Patients With Kidney Transplant Using Ultrasound Localization Microscopy and Multispectral Optoacoustic Tomography","ESTIMATOR","Inclusion Criteria:\n\n* kidney transplant\n* indication for biopsy set in clinical routine\n* minimum 18 years of age\n* written consent\n\nExclusion Criteria:\n\n* allergy against contrast agents\u002F SonoVue\n* tatoos in examined areas\n* contraindication against SonoVue\n* pregnant women\n* breast feeding women",{"count":526,"type":21},"In this study, the condition of the kidney transplant in adults is to be assessed non-invasively using Multispectral Optoacoustic Tomography and Ultrasound Localization Microscopy (ULM). ULM imaging can be performed in a 2-dimensional and a 3-dimensional way (2D and 3D ULM). Therefore, \"ULM\" in the following texts and measures will refer to 2D and 3D ULM.\n\nNew, non-invasive markers that allow conclusions to be drawn about the condition of the transplant should reduce the need for invasive diagnostic procedures in the future.",[27,550],"Kidney Biopsy","2026-03-02",{"date":553,"type":40},"2026-03-04",{"date":555,"type":40},"2024-06-18",{"date":557,"type":21},"2028-01-18",{"name":559,"class":47},"University of Erlangen-Nürnberg Medical School",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":576,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":300},"100608632","phase-2-tnx-1500-in-kidney-transplant-recipients-100608632","NCT07204080","(TNX-1500) in Kidney Transplant Recipients","Phase II Clinical Trial Evaluating the Safety and Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients","TONIX-1500","Inclusion Criteria:\n\n1. Male or female subjects ≥18 to 75 years of age.\n2. Kidney transplant candidates with chronic kidney disease (stage IV or V) or end-stage kidney disease evaluated and listed for transplantation at Massachusetts General Hospital.\n3. Recipient of an ABO-compatible, non-human leukocyte antigen (HLA) identical living or deceased donor kidney (de novo or second transplant)\n4. Ability to understand the study requirements and provide written informed consent.\n5. Epstein-Barr virus (EBV) seropositive\n\nExclusion Criteria:\n\n1. Recipient seropositive for human immunodeficiency virus (HIV-1), or hepatitis B surface antigen (HBsAg) or core antibody (Anti-HBc); subjects who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response (SVR) after anti-HCV treatment or spontaneous clearance.\n2. Recipient of a kidney from a donor who tests positive for HIV, HBsAg, Anti-HBc, or HCV NAT.\n3. Subjects with a severe systemic infection, current or within the 2 weeks prior to screening.\n4. Left ventricular ejection fraction \\\u003C 40% as determined by TTE or clinical evidence of heart failure.\n5. Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test.\n6. Women of childbearing potential (women capable of becoming pregnant) unless using a highly effective method of contraception during dosing and for 24 weeks after study treatment. Highly effective contraception methods include:\n\n   1. Female sterilization (surgical, bilateral oophorectomy with or without hysterectomy), or tubal ligation at least 6 weeks before taking study treatment.\n   2. Male sterilization (at least 6 months prior to screening); for female subjects on the study, the vasectomized male partners should be the sole partners for that subject.\n   3. Use of injected or implanted hormonal methods of contraception or other hormonal contraception that have comparable efficacy (\\\u003C1% for example, hormone vaginal ring or placement of a long-acting reversible contraceptives, an intrauterine device, or intrauterine system.\n   4. Total abstinence\n7. Use of other investigational products or enrollment in another investigational drug study within 30 days prior to screening or 5 half-lives, whichever is longer.\n8. Subjects with clinically significant lab abnormalities (\\>2.5 x the upper limit of normal (ULN) of the following liver function chemistries unless due to, as judged by the investigator, a benign underlying condition:\n\n   1. Alanine aminotransferase (ALT)\n   2. Aspartate aminotransferase (AST)\n   3. Alkaline phosphatase (ALP)\n   4. Bilirubin\n   5. Coagulation studies (international normalization ratio (INR), prothrombin time (PT), and partial thromboplastin time (PTT))\n9. Any other clinically significant medical condition, active infection, laboratory abnormality, or psychosocial condition (e.g. history of substance use disorder) that would, in the judgement of the investigator, impact the subject's ability to participate in the trial.\n10. Subject receives an organ at high risk for delayed graft function, including from a deceased donor after cardiac death (DCD) or a high Kidney Donor Profile Index ≥85%.\n11. Presence of pre-existing donor-specific antibodies (DSA) or calculated panel reactive antibodies (cPRA) \\>20% based upon results within 6 months prior to transplant.\n12. Virtual crossmatch (VXM) positive transplant with an MFI \\>1000 as assessed by routine methodology (Luminex)\n13. Cytomegalovirus (CMV) high risk combination: donor positive to recipient negative\n14. Multi-organ transplant or tissue recipient.\n15. History of malignancy of any organ system, except for localized excised non-melanomatous skin or carcinoma in situ of the cervix\n16. Subjects with any of the following: hemoglobin \\\u003C8 mg\u002FdL, white blood cell ≤2,000\u002Fmm3, or platelet count ≤75,000\u002Fmm3.","75 Years",{"count":407,"type":21},[230],"The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.",[27,573,574,575],"Kidney Transplant Failure and Rejection","Immunosuppression","Immunosuppression After Kidney Transplantation",[27,577],"New Immunosuppression","2026-02-24",{"date":580,"type":40},"2026-02-25",{"date":78,"type":21},{"date":583,"type":21},"2029-06-30",{"name":585,"class":47},"Ayman Al Jurdi, MD",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":568,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":610},"100586717","phase-2-improving-deceased-donor-kidney-transplant-outcomes-via-a-single-intragraft-injection-of-c1-esterase-inhibitor-improve-trial-100586717","NCT06919003","Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)","Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (RTB-021)","IMPROVE","Inclusion Criteria:\n\n1. Participant must be able to understand and provide informed consent\n2. Adults who are on chronic dialysis therapy and are on the wait list for deceased donor kidney transplant\n3. Recipients who are ABO compatible with donor allograft\n4. Negative crossmatch and no donor specific anti-HLA antibody (DSA) on most recent pretransplant serum sample as determined by local site\n5. Female participants of childbearing potential must have a negative pregnancy test upon study entry\n6. All participants with reproductive potential must agree to use highly effective contraception for at least 12-moths post-transplant. Oral estrogen containing contraception must not be used during the first 3 months post-transplant\n7. Hepatitis C Virus Ab positive participants with negative Hepatitis C virus (HCV) Polymerase chain reaction (PCR) are eligible if they have spontaneously cleared infection or are in sustained virologic remission\n8. Hepatitis C Virus negative recipients of a Hepatitis C Virus positive organ are eligible if they will be treated with the intent of inducing a sustained virologic remission\n9. Recipients of kidneys arriving to the transplant center on ex vivo hypothermic machine perfusion pumps are eligible\n10. Recipients of kidneys that received in situ normothermic regional perfusion in the donor are eligible. Kidneys that received normothermic machine perfusion after organ procurement (ex situ normothermic perfusion) are not eligible (See Exclusion #4)\n11. Anticipated Cold Ischemia Time (CIT) \\>=12 hours\n12. Kidney Donor Profile Index (KDPI) 21-95%. For KDPI 21-34% to be eligible, anticipated CIT must be \\>=24 hours\n13. Patients with normal coagulation\n\nExclusion Criteria:\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n2. Any prior or concurrent non-renal solid organ, or cellular transplant, or waitlisted for multi-organ transplant. Prior autologous transplant is allowed\n3. Patients receiving enbloc kidneys\n4. Kidneys that received ex vivo normothermic machine perfusion after procurement. Kidneys that received in situ normotherimic regional perfusion in the donor are eligible (see Inclusion #10)\n5. Patients with a known pro-thrombotic disorder\n6. Patients with a history of thrombosis or hyper-coagulable state, excluding dialysis access clotting or other superficial vein thrombosis not requiring long-term systemic treatment\n7. Body mass index (BMI) \\>=40 kg\u002Fm\\^2\n8. Patients with a history of Hereditary Angioedema or use of C1 esterase inhibitor (C1INH) containing products or recombinant C1INH within 15 days prior to study entry\n9. Patients with a known hypersensitivity to treatment with Berinert\n10. Patients requiring chronic anti-coagulation or anti-platelet therapy. ASA and NSAIDS are allowed\n11. Presence of active malignancy or history of malignancy less than 5 years in remission, excluding adequately treated in-situ cervical carcinoma, low grade prostate carcinoma, renal cell carcinoma stage T1N0M0 that has been treated with nephrectomy, or adequately treated basal or squamous cell carcinoma of the skin\n12. Patients who are positive for Hep B infection (Hepatitis B surface antigen (HBsAg)+); patients with HbcAB+ are eligible if HBV PCR is negative\n13. Any active infection\n14. Human immunodeficiency virus (HIV) infection\n15. Enrollment in another investigational trial\n16. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of enrollment\n17. Current or planned use of immunomodulatory agents including but not limited to rituximab, belatacept, eculizumab, JAK inhibitors, anti-TNF agents\n18. Female participants who are pregnant or lactating\n19. Past or current medical problems, inclusive of mental health and substance abuse concerns, or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study\n20. History of any stroke (including ischemic, hemorrhagic, or embolic) within the previous 6 months",{"count":595,"type":21},180,[230],"The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned.\n\nThe primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)",[27],[263,600,601,602],"Deceased donor","Intragraft injection","C1 esterase inhibitor",{"date":604,"type":40},"2026-02-27",{"date":606,"type":40},"2025-09-22",{"date":608,"type":21},"2032-05-30",{"name":244,"class":245},4,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":619,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":630,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":4},"100625231","older-kidney-patient-optimisation-pretransplant-100625231","NCT07419945","Older Kidney Patient Optimisation Pretransplant","Optimising Access to and Outcomes From Transplantation in Older Potential Kidney Transplant Recipients: Pilot Feasibility Study on Kidney Transplant-specific Comprehensive Geriatric Assessment (KT-CGA)","OK-POP","Inclusion Criteria:\n\n* Adults aged 60 years or older\n* Attending Guy's and St Thomas' (GSTT) Nephrology services\n* Diagnosed with Chronic Kidney Disease (CKD) Stage 5\n\nEither:\n\n* Pre-dialysis, or\n* Receiving dialysis (in-centre haemodialysis, peritoneal dialysis, or home haemodialysis)\n* Referred to the kidney transplant surgical clinic for assessment of suitability for kidney transplantation (pre-transplant evaluation)\n\nExclusion Criteria:\n\n* Adults aged under 60 years\n* Patients currently attending the Nephrology Supportive Care service at GSTT","60 Years",{"count":621,"type":21},50,[24],"The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation. The main questions it aims to answer are:\n\nIs it feasible and acceptable to deliver a KT-CGA alongside routine transplant assessment in older adults with advanced kidney disease?\n\nWhat is the effect of KT-CGA on decision-making about transplant listing and on patient-reported outcomes such as quality of life and frailty?\n\nResearchers will compare participants who receive the KT-CGA plus usual care to those who receive usual care alone.\n\nParticipants will:\n\nContinue with their usual transplant assessment process\n\nIf randomised to the intervention group, also complete the KT-CGA (a structured set of questionnaires, short memory and function tests, and discussions about wellbeing and support needs, taking about 45-60 minutes)",[64,260,625,626,627,628,27,629],"Frailty","Cognitive Impairment","Multimorbidity","End Stage Kidney Disease (ESRD)","Health Inequity",[31,631,632,633,634,635],"frailty","multimorbidity","cognitive impairment","end stage kidney disease","health inequality","2026-02-12",{"date":638,"type":40},"2026-02-19",{"date":640,"type":21},"2026-02-02",{"date":642,"type":21},"2028-02-02",{"name":644,"class":47},"Guy's and St Thomas' NHS Foundation Trust",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":653,"enrollmentInfo":654,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":655,"conditions":656,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":300},"100579913","ktrsensor-scotland-study-an-observational-study-into-predictors-and-diagnosis-of-kidney-transplant-rejection-100579913","NCT06830473","KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection","KTRSensor Scotland Study: Investigating the Role of Biomarkers in Kidney Transplant Outcomes","KTRSensors","Any patient within a Scottish Transplant centre who has undergone renal transplant (+\u002F- pancreas\u002Fislet) and is due to attend routine follow-up appointments at the index centre.\n\nExclusion criteria:\n\n* no previous kidney transplant\n* patient attending follow-up at a peripheral site\n* unable to provide urine samples across the study duration","99 Years",{"count":228,"type":21},"An observational study capturing real world transplant patients in the post-operative setting aiming to further determine the utility of biomarkers to improve outcomes.",[27,657],"Kidney Disease, Chronic","2026-02-09",{"date":660,"type":40},"2026-02-10",{"date":662,"type":40},"2025-05-16",{"date":664,"type":21},"2028-05-13",{"name":666,"class":47},"University of Edinburgh"]